Stockreport

Zogenix Announces Positive Top-line Results from Global Pivotal Phase 3 Trial of FINTEPLA® for the Treatment of Lennox-Gastaut Syndrome

Zogenix, Inc.  (ZGNX) 
Last zogenix, inc. earnings: 3/2 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: zogenixinc.gcs-web.com/investor-overview
PDF Primary Endpoint Achieved - Statistically Significant Reduction in Drop Seizures for FINTEPLA 0.7 mg/kg/day versus Placebo FINTEPLA Also Demonstrated Statistically Signi [Read more]